



82-4867

amrad corporation limited  
abn 37 006 614 375  
576 swan street richmond  
victoria australia 3121  
telephone (61 3) 9208 4000  
facsimile (61 3) 9208 4356  
<http://www.amrad.com.au>

RECEIVED  
2004 JUL -1 A 8:18  
OFFICE OF INTERNATIONAL  
CORPORATE FINANCE

To: The Securities and Exchange Commission

Company:

Fax: 0011 1 202 942 9624

From: Robyn Fry - Company Secretary

Fax: (+61 3) 9208 4356

Date: 1 July 2004

Pages: 5  
Including cover page



04035206

SUPPL

*This document and any following pages are intended solely for the named addressee, are confidential and may contain legally privileged information. The copying or distribution of them or any information they contain, by anyone other than the addressee, is prohibited. If you have received this document in error, please let us know by telephone, and then return it by mail to the address above. We shall refund your costs of doing so.*

## FACSIMILE COVER SHEET


### Amrad Corporation Limited

Please find attached information being furnished by Amrad Corporation Limited to the Securities and Exchange Commission.

*R. Fry*  
Robyn Fry  
General Counsel & Company Secretary

*Ilw 7/6*

PROCESSED  
JUL 06 2004  
THOMSON  
FINANCIAL *B*



amrad corporation limited  
abn 37 006 614 375  
576 swan street richmond  
victoria australia 3121

telephone (61 3) 9208 4000  
facsimile (61 3) 9208 4352  
<http://www.amrad.com.au>

FILE No.  
82-4867

1 July 2004

Securities and Exchange Commission  
Division of Corporate Finance  
450 Fifth Street NW  
WASHINGTON DC 20549  
USA


Dear Sirs

**AMRAD Corporation Limited**  
**Rule 12g3-2(b) Exemption (File No. 82-4867)**

The enclosed information is being furnished by AMRAD Corporation Limited ("AMRAD") under paragraph (b)(1)(i) of Rule 12g3-2 under the Securities Exchange Act of 1934 ("the Exchange Act"). AMRAD's file number is indicated in the upper right hand corner of each unbound page and the first page of each bound document furnished herewith.

In accordance with paragraphs (b)(4) and (b)(5) of the Rule, the documents furnished herewith are being furnished with the understanding that such documents will not be deemed "filed" with the Securities and Exchange Commission or otherwise subject to the liabilities of Section 18 of the Exchange Act, and that neither this letter nor the furnishings of such documents shall constitute an admission for any purpose that AMRAD is subject to the Exchange Act.

Yours sincerely

P.P. 

**Robyn Fry**  
**General Counsel & Company Secretary**

FILE NO.  
82-4867Rule 12g3-2(b) Card Received from the SEC

ISSUER AMRAO Corporation Limited	FILE NO. 82- 4867
-------------------------------------	----------------------

9/4/98

This will advise that the issuer has been added to the list of those foreign private issuers that claim exemption pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Please be further advised that in order to continue to claim this exemption, the issuer must furnish to the Commission, on a timely basis, all information required by Rule 12g3-2(b). This includes all relevant documents since the date of your initial submission. The burden of furnishing such information rests with the issuer, even if it delegates that responsibility to another, and the staff will look to the issuer for compliance. If the issuer is a member of an affiliated or control group which normally prepares reports, press releases, etc., in a single document, a separate report must be submitted for each issuer that claims an exemption under the rule because separate files are maintained for each issuer.

ALL FUTURE SUBMISSIONS MUST PROMINENTLY INDICATE THE EXEMPTION NUMBER IN THE UPPER RIGHT HAND CORNER OF EACH UNBOUND PAGE AND THE FIRST PAGE OF EACH BOUND DOCUMENT PURSUANT TO THE IDENTIFICATION PROVISIONS OF THE RULE. FAILURE TO SO INDICATE WILL RESULT IN THE SUBMISSION BEING RETURNED TO THE SENDER AND THE SUBMISSION NOT BEING RECORDED, RESULTING IN POSSIBLE LOSS OF THE EXEMPTION.

**ASX**

AUSTRALIAN STOCK EXCHANGE

LE No.  
4867

Australian Stock Exchange Limited  
ABN 98 008 624 691  
Exchange Centre  
Level 4, 20 Bridge Street  
Sydney NSW 2000

PO Box H224  
Australia Square  
NSW 1215

Telephone 61 2 9227 0334

Internet <http://www.asx.com.au>  
DX 10427 Stock Exchange Sydney

**FACSIMILE****Department: COMPANY ANNOUNCEMENTS OFFICE**

DATE: 01/07/2004

TIME: 09:12:28

TO: AMRAD CORPORATION LIMITED

FAX NO: 03-9208-4356

FROM: AUSTRALIAN STOCK EXCHANGE LIMITED - Company Announcements Office

SUBJECT: CONFIRMATION OF RECEIPT AND RELEASE OF ANNOUNCEMENT

**MESSAGE:**

We confirm the receipt and release to the market of an announcement regarding:

**Avexa Demerger-Temp Suspension of Share Buy-Back**

**PLEASE NOTE:**

In accordance with Guidance Note 14 of ASX Listing Rules –

- Use of ASX Online for lodgement of company announcements becomes mandatory from **1 July 2003**
- **Handwritten** and **hand-delivered** company announcements are no longer accepted
- Fee of A\$38.50 (including GST) applies from **1 March 2003** for announcements **faxed** to CAP
- New CAP fax number from **1 March 2003** for announcements sent within Australia is **1900 999 279**

FILE No.  
82-4867

amrad corporation limited  
abn 37 006 614 375  
576 swan street richmond  
victoria australia 3121  
telephone (61 3) 9208 4320  
facsimile (61 3) 9208 4352  
<http://www.amrad.com.au>

Thursday, 1 July 2004

#### **AVEXA DEMERGER - TEMPORARY SUSPENSION OF SHARE BUY-BACK**

On 21<sup>st</sup> June, Amrad announced its intention to demerge its anti-infectives business, Avexa Limited, and to list Avexa on the Australian Stock Exchange later this year.

Under the terms of the demerger, which is subject to approval by shareholders, Amrad shareholders will receive shares in Avexa on a pro-rata basis to their current holdings of Amrad shares. Importantly, Amrad shareholders will not be required to contribute any cash in order to obtain their shares in Avexa. Amrad shareholders' current holdings of Amrad shares will be unaffected.

To enable the calculation of the entitlements of Amrad shareholders for inclusion in the demerger documentation, it is necessary to determine now the total number of Amrad shares that will be on issue at the Record Date for the offer.

In order that this number remains fixed during the demerger process to allow precise calculation of entitlements, Amrad advises that it will temporarily suspend purchase of shares under its current share buy-back program until after the Record Date of the Avexa offer.

Avexa is developing novel therapies that could represent early market entrants in new drug classes for the treatment of major diseases including HIV/AIDS, Hepatitis B and antibiotic resistant bacterial infections.

#### **About Amrad:**

Amrad Corporation Limited is an Australian drug discovery and development based biotechnology company. Amrad's in-house R&D expertise is focused on a number of priority projects in the areas of allergy, inflammation and infectious diseases. Further information about projects in drug discovery and development can be found at [www.amrad.com.au](http://www.amrad.com.au).

#### **Further information:**

Mr Bob Moses  
Chairman  
0412 211 018

Dr Pete Smith  
CEO  
03 9208 4108

Doc# 120495 v6

A biotechnology research & development company